SAN DIEGO - Illumina urged its shareholders Monday to reject a sweetened buyout offer from the Swiss drugmaker Roche, saying that the $6.5 billion deal still undervalues the California maker of genetic analysis instruments.
126745
Illumina urges shareholders to reject buyout
93778
Pharmaxis shares dive after US review
60565
Orexigen Therapeutics Inc reports grant of inducement stock option
16793
Morgan Stanley downgrades RIL to 'underweight'
21741
Roche launches takeover bid for US firm Illumina
161638
US stocks remain lower;
103487
Emkay recommends `Hold ` on Sun Pharma
57640
Drug stocks slide with broader market
59800
Morgan Stanley maintains underweight rating on SBI
98876
Crescendo raises GBP4.5m for development of antibody technology platforms
81826
Equities aren't a bargain
175334
Share prices open lower today
68942
HPCL a undervalued stock:
31818
Risk appetite remains on the defensive
108391
Nasdaq and ICE drop $11.3bn bid for NYSE Euronext
62106
Goldman Small Cap research issues research update on Rexahn Pharmaceuticals, Inc.
114631
Talbots rejects buyout offer